MENU
+Compare
PTGX
Stock ticker: NASDAQ
AS OF
Dec 26 closing price
Price
$88.78
Change
-$0.06 (-0.07%)
Capitalization
5.55B

PTGX Protagonist Therapeutics Forecast, Technical & Fundamental Analysis

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs... Show more

Industry: #Biotechnology
PTGX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for PTGX with price predictions
Dec 26, 2025

Aroon Indicator for PTGX shows an upward move is likely

PTGX's Aroon Indicator triggered a bullish signal on December 23, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 280 similar instances where the Aroon Indicator showed a similar pattern. In of the 280 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 51 cases where PTGX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PTGX advanced for three days, in of 312 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for PTGX moved out of overbought territory on December 16, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 48 similar instances where the indicator moved out of overbought territory. In of the 48 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on December 24, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on PTGX as a result. In of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for PTGX turned negative on December 17, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PTGX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

PTGX broke above its upper Bollinger Band on December 12, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PTGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.598) is normal, around the industry mean (26.614). P/E Ratio (134.515) is within average values for comparable stocks, (51.532). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.867). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. P/S Ratio (27.248) is also within normal values, averaging (310.546).

View a ticker or compare two or three
PTGX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

PTGX is expected to report earnings to fall 45.11% to -34 cents per share on March 18

Protagonist Therapeutics PTGX Stock Earnings Reports
Q4'25
Est.
$-0.34
Q3'25
Beat
by $0.01
Q2'25
Beat
by $0.03
Q1'25
Missed
by $0.12
Q4'24
Beat
by $1.79
The last earnings report on November 06 showed earnings per share of -62 cents, beating the estimate of -62 cents. With 390.11K shares outstanding, the current market capitalization sits at 5.55B.
A.I. Advisor
published General Information

General Information

a developer of disulfide-rich peptides

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
7707 Gateway Boulevard
Phone
+1 510 474-0170
Employees
112
Web
https://www.protagonist-inc.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RMFGX60.050.01
+0.02%
American Funds American Mutual R6
HLFMX8.95N/A
N/A
Harding Loevner Frontier Emerg Mkts Inst
FSAGX61.05N/A
N/A
Fidelity Select Gold
GSMAX18.62-0.04
-0.21%
Goldman Sachs Small/Mid Cap Growth A
HIGUX19.28-3.57
-15.62%
Carillon Eagle Growth & Income R6

PTGX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, PTGX has been loosely correlated with BIESF. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if PTGX jumps, then BIESF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTGX
1D Price
Change %
PTGX100%
+0.12%
BIESF - PTGX
61%
Loosely correlated
N/A
TRVI - PTGX
43%
Loosely correlated
+1.17%
DNLI - PTGX
41%
Loosely correlated
+1.07%
ORMP - PTGX
37%
Loosely correlated
+6.78%
MLYS - PTGX
37%
Loosely correlated
+0.21%
More

Groups containing PTGX

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PTGX
1D Price
Change %
PTGX100%
+0.12%
PTGX
(2 stocks)
100%
Closely correlated
-0.03%